Amylin Pharmaceuticals Inc. entered a global agreement with Eli Lilly and Co. to collaborate on the development and commercialization of Amylin's late-stage Type II diabetes candidate, AC2993, in a deal that could mean more than $435 million for the biotech company. (Bioworld Today) Read More
